The HDAC1 Knockout HAP1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population in which the HDAC1 gene has been genetically disrupted in the near-haploid human HAP1 cell line. This polyclonal pool, derived following CRISPR/Cas9-mediated target-gene disruption, provides a heterogeneous loss-of-function model without clonal isolation, enabling robust experimental replication across multiple independent knockout events.
The HAP1 parental line is a human haploid cell line originally derived from the KBM-7 chronic myeloid leukemia cells. Its near-haploid karyotype, with a single copy of most chromosomes, minimizes allelic redundancy and simplifies functional genomic studies. HAP1 cells are widely employed in genetic screening, reverse genetics, and pathway dissection, offering a reproducible platform for investigating gene function in a human cellular context.
HDAC1 encodes a class I histone deacetylase that functions as a core catalytic subunit within multiprotein corepressor complexes, including Sin3, NuRD, and CoREST. Within these complexes, HDAC1 interacts with scaffold proteins such as SIN3A, SAP30, RBBP4, MTA2, and RCOR1 to remove acetyl groups from key lysine residues on histone H3 (Lys9, Lys14) and histone H4 (Lys5, Lys8, Lys12, Lys16), leading to chromatin condensation and transcriptional repression. HDAC1 also deacetylates non-histone targets, notably p53 at Lys320 and Lys373, thereby modulating its tumor-suppressor activity, and regulates transcription factors E2F1, MyoD, STAT1, and NF-??B. Upstream regulation involves phosphorylation by CK2, sumoylation, and association with cell cycle regulators RB1 and E2F1. Disruption of HDAC1 results in hyperacetylation of these substrates, impacting cell cycle progression, apoptosis, and gene expression programs linked to cancer and neurodegeneration.
In the HAP1 haploid background, HDAC1 knockout cells provide a uniquely tractable model for dissecting epigenetic regulatory mechanisms. The single-allele status enhances the penetrance of the knockout phenotype, allowing clean assessment of HDAC1-dependent functions without interference from a second allele. This system is particularly valuable for chemical probe and HDAC inhibitor validation, as the lack of functional HDAC1 enables straightforward on-target efficacy testing. Moreover, the combination of haploidy and polyclonality offers a cost-effective and statistically robust alternative to monoclonal knockout lines for large-scale screens.
These HDAC1 knockout HAP1 cells are suitable for a range of experimental applications, including Western blot detection of global histone acetylation, chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) to map HDAC1-dependent acetylation marks at specific genomic loci, and quantitative RT-PCR or RNA-sequencing to profile transcriptional changes. Flow cytometry can be used to monitor cell cycle alterations and apoptosis induction, while HDAC activity assays and co-immunoprecipitation facilitate biochemical characterization of deacetylase function and complex integrity. The polyclonal population supports HDAC inhibitor selectivity and cytotoxicity screening in cancer models and studies of pathways related to acute myeloid leukemia, breast cancer, and neurological disorders. For further technical details and ordering information, please contact Ascent Research.
